The first objective is to better identify the remaining unmet needs of patients and to direct R&D efforts where they ... industry in 1996 when he joined Merck, Sharp & Dohme (MSD) at the UK ...

On Oct. 15, Modifi Bio, a Yale-based biotech company, closed an acquisition deal with Merck, an American pharmaceutical ...

He was a pioneer of new methods in the industry, being one of the first to focus on R&D as well as manufacturing ... whilst “American” Merck (now Merck & Co. in the US or Merck Sharp ...

Vaccinex has global commercial and development rights to pepinemab and is the sponsor of the KEYNOTE-B84 study which is being performed in collaboration with Merck Sharp & Dohme Corp, a subsidiary of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement. Investors should monitor R&D updates closely ...

M.D., Ph.D., vice president of discovery oncology at Merck Research Laboratories, said in the release. “The talented Modifi Biosciences team has developed an innovative approach that we believe ...

Oct 17 (Reuters) - (This Oct. 17 story has been corrected to say that the drug reduced some types of respiratory infection, not all, in the headline and paragraphs 1 and 2) Merck (MRK.N), opens ...

Ph.D., said in a company release. Merck, too is "pleased" with the vote, a company spokesperson said in an emailed statement. "This recommendation to lower the age-based recommendation is a ...

(Reuters) - Merck has acquired Modifi Biosciences for as much as $1.3 billion, gaining access to its experimental cancer therapies, the privately held biotech firm said on Wednesday. As part of ...

Merck KGaA said it’s seeing the beginning of a post-Covid pandemic rebound in life sciences as it reaffirmed the group’s sales and profit guidance for the full year. The German science and ...

Enrollment on track in Phase 2 portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS ...